Royalty Pharma plc
RPRX
$31.17
$0.040.13%
| Weiss Ratings | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | B | |||
| Rating Factors | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Good | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.35 | |||
| Price History | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.96% | |||
| 30-Day Total Return | -3.04% | |||
| 60-Day Total Return | 23.00% | |||
| 90-Day Total Return | 22.09% | |||
| Year to Date Total Return | 21.66% | |||
| 1-Year Total Return | 7.43% | |||
| 2-Year Total Return | -9.67% | |||
| 3-Year Total Return | -13.17% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -8.27% | |||
| 52-Week Low % Change | 30.44% | |||
| Price | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $34.20 | |||
| 52-Week Low Price | $24.05 | |||
| 52-Week Low Price (Date) | Dec 19, 2024 | |||
| 52-Week High Price (Date) | Feb 24, 2025 | |||
| Valuation | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.59B | |||
| Enterprise Value | 23.61B | |||
| Price/Earnings (TTM) | 17.39 | |||
| Earnings Per Share (TTM) | 1.80 | |||
| Earnings Per Share Growth | -28.88% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 8.16 | |||
| Price/Book (Q) | 2.01 | |||
| Enterprise Value/Revenue (TTM) | 10.43 | |||
| Price | $31.17 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | 18.27 | |||
| Market Cap Category | Large Cap | |||
| Dividends and Shares | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 589.00M | |||
| Dividend Yield | 2.71% | |||
| Div. Per Share (Most Recent) | $0.22 | |||
| Dividend Per Share (TTM) | $0.85 | |||
| Payout Ratio (TTM) | 43.83% | |||
| Dividend Per Share (Most Recent) | $0.22 | |||
| Company Info | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 212 883 0200 | |||
| Address | 110 East 59th Street New York, NY 10022 | |||
| Website | www.royaltypharma.com | |||
| Country | United States | |||
| Year Founded | 1996 | |||
| Profitability | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 57.09% | |||
| Profit Margin | 37.94% | |||
| Management Effectiveness | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 4.67% | |||
| Return on Equity | 13.03% | |||
| Income Statement | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.26B | |||
| Total Revenue (TTM) | 2.26B | |||
| Revenue Per Share | $3.84 | |||
| Gross Profit (TTM) | 1.53B | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | 1.29B | |||
| Net Income (TTM) | 858.98M | |||
| Net Income Avl. to Common (TTM) | 858.98M | |||
| Total Revenue Growth (Q YOY) | -0.41% | |||
| Earnings Growth (Q YOY) | -53.41% | |||
| EPS Diluted (TTM) | 1.80 | |||
| EPS Diluted Growth (Q YOY) | -68.08% | |||
| Balance Sheet | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 987.23M | |||
| Cash Per Share (Q) | $1.68 | |||
| Total Current Assets (Q) | 1.80B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 10.34B | |||
| Current Ratio (Q) | 1.438 | |||
| Book Value Per Share (Q) | $15.58 | |||
| Total Assets (Q) | 18.22B | |||
| Total Current Liabilities (Q) | 1.25B | |||
| Total Debt (Q) | 7.61B | |||
| Total Liabilities (Q) | 7.88B | |||
| Total Common Equity (Q) | 6.95B | |||
| Cash Flow | RPRX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -2.68B | |||
| Cash from Financing (TTM) | 361.15M | |||
| Net Change in Cash (TTM) | 452.02M | |||
| Levered Free Cash Flow (TTM) | -1.76B | |||
| Cash from Operations (TTM) | 2.77B | |||
